Recursion Pharmaceuticals

recursionpharma.com

Recursion is a clinical-stage biotechnology company combining experimental biology and automation with artificial intelligence in a massively parallel system to efficiently discover potential drugs for diverse indications, including genetic disease, inflammation, immunology, and infectious disease. Recursion applies causative perturbations to human cells to generate disease models and associated biological image data. Recursion’s rich, relatable database of more than a petabyte of biological images generated in-house on the company’s robotics platform enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics to radically improve lives. Recursion is headquartered in Salt Lake City.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

TSCAN AND NOVARTIS PARTNER TO DEVELOP CANCER THERAPIES

Pharmaceutical Technology | April 16, 2020

news image

Biopharmaceutical firm TScan Therapeutics has signed an agreement with Novartis to discover and develop therapies for the treatment of cancer. The companies aim to work on TCR-engineered T-cell therapies for solid tumours. TScan’s platform will identify cancer antigens that could be targeted by TCR-based treatments. As part of the deal, TScan will find and characterise TCRs while Novartis will hold an option to licence and develop TCRs for up to three new targets. Furthermore, Novartis wil...

Read More

PHARMA GIANT ROCHE GETS US GO-AHEAD FOR COVID-19 ANTIBODY TEST

The guardian | May 03, 2020

news image

Swiss drug maker Roche Holding AG says it has received emergency use approval from the US Food and Drug Administration (FDA) for an antibody test to help determine if people have ever been infected with the coronavirus. Governments, businesses and individuals are seeking such blood tests to help them learn more about who may have had the disease, who may have some immunity and to potentially craft strategies to end lockdowns that have battered global economies. Roche had previously pledged to ma...

Read More

PARALLEL'S SURTERRA WELLNESS STORES TO INTRODUCE NEW PRODUCTS INCLUDING EDIBLES IN FLORIDA

Prnewswire | August 31, 2020

news image

Parallel, formerly known nationally as Surterra Holdings, a company pioneering well-being through its proprietary cannabinoid brands, science and technology-led innovation, today announced that it will introduce new edible cannabis products to its customers in its 39 Florida Surterra Wellness stores. This expansion of Surterra Wellness' product offering follows the Florida Department of Health's (FDOH) finalizing recently released emergency rules to allow for the production and sale of e...

Read More

Pharmacy Market

TRIALCARD LAUNCHES ENGAGE HCP

TrialCard | August 31, 2021

news image

TrialCard Incorporated today announced the launch of Engage HCP by TrialCard, a new expanded suite of services that serves as a complement to a biopharma brand's field teams, while delivering measurable results in brand reach, lead generation, and market share growth. Engage HCP by TrialCard is designed to offer a flexible array of services that can serve as standalone teams or be used to bolster the efforts of existing field teams. Engage HCP offers HCP engagement servi...

Read More
news image

TSCAN AND NOVARTIS PARTNER TO DEVELOP CANCER THERAPIES

Pharmaceutical Technology | April 16, 2020

Biopharmaceutical firm TScan Therapeutics has signed an agreement with Novartis to discover and develop therapies for the treatment of cancer. The companies aim to work on TCR-engineered T-cell therapies for solid tumours. TScan’s platform will identify cancer antigens that could be targeted by TCR-based treatments. As part of the deal, TScan will find and characterise TCRs while Novartis will hold an option to licence and develop TCRs for up to three new targets. Furthermore, Novartis wil...

Read More
news image

PHARMA GIANT ROCHE GETS US GO-AHEAD FOR COVID-19 ANTIBODY TEST

The guardian | May 03, 2020

Swiss drug maker Roche Holding AG says it has received emergency use approval from the US Food and Drug Administration (FDA) for an antibody test to help determine if people have ever been infected with the coronavirus. Governments, businesses and individuals are seeking such blood tests to help them learn more about who may have had the disease, who may have some immunity and to potentially craft strategies to end lockdowns that have battered global economies. Roche had previously pledged to ma...

Read More
news image

PARALLEL'S SURTERRA WELLNESS STORES TO INTRODUCE NEW PRODUCTS INCLUDING EDIBLES IN FLORIDA

Prnewswire | August 31, 2020

Parallel, formerly known nationally as Surterra Holdings, a company pioneering well-being through its proprietary cannabinoid brands, science and technology-led innovation, today announced that it will introduce new edible cannabis products to its customers in its 39 Florida Surterra Wellness stores. This expansion of Surterra Wellness' product offering follows the Florida Department of Health's (FDOH) finalizing recently released emergency rules to allow for the production and sale of e...

Read More
news image

Pharmacy Market

TRIALCARD LAUNCHES ENGAGE HCP

TrialCard | August 31, 2021

TrialCard Incorporated today announced the launch of Engage HCP by TrialCard, a new expanded suite of services that serves as a complement to a biopharma brand's field teams, while delivering measurable results in brand reach, lead generation, and market share growth. Engage HCP by TrialCard is designed to offer a flexible array of services that can serve as standalone teams or be used to bolster the efforts of existing field teams. Engage HCP offers HCP engagement servi...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us